Isabella Caroline de Oliveira Barretto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabella Caroline de Oliveira Barretto has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Cezar Aquino de Moraes
University of São Paulo
2 shared publications - Nayara Rozalem Moretti
Medical School of Presidente Prudente, University of Western São Paulo (UNOESTE), Presidente Prudente, Brazil
2 shared publications - Ana Laura Ayumi Zanoni Chiba
Department of Medicine, University of Western São Paulo
1 shared publication - Angélica Augusta Grigoli Dominato
Universidade do Oeste Paulista
1 shared publication - Barbara Antonia Dups Talah
Pontifical Catholic University of Paraná, Curitiba, Brazil
1 shared publication - Bárbara de Moura Moreira
Department of Medicine, University of Western São Paulo
1 shared publication
Latest Publications
- 17 October 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (4) , 1324-1339
Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis
Background Endometrial cancer (EC) is the sixth most common female cancer and may rank fourth in cancer mortality by 2040. TP53 mutations and aberrant p53 expression are associated to aggressive tumor subtypes and poor prognosis, reducing overall survival (OS), disease-free survival, recurrence rates (RcR) and Mortality Risk (MR). The prognostic impact of TP53 mutations in EC remains unclear. Methods A systematic search was conducted in PubMed, Embase, and the Cochrane Library. Hazard ratios (HR) and Risk Ratios (RR) with 95% confidence intervals (CI) were combined using random-effects models. Analyses were conducted in RStudio (v4.4.1), and heterogeneity was evaluated using the I2 statistic, with p < 0.05 considered significant. Results Twenty-four studies comprising 5462 EC patients were included. TP53 mutations and aberrant p53 expression were associated with poorer outcomes. For OS, TP53 mutations had an HR of 2.27 (95% CI 1.47–3.49) and aberrant p53 had an HR of 5.01 (95% CI 2.44–10.30). For DFS, TP53 mutations had an HR of 4.20 (95% CI 1.79–9.86), while aberrant p53 had an HR of 2.17 (95% CI 1.27–3.72). TP53 mutations also increased RcR (RR: 2.88; 95% CI 2.18–3.80) and MR (RR: 2.33; 95% CI 1.11–4.88). Aberrant p53 showed a non-significant trend for recurrence (RR: 3.54; 95% CI 0.95–13.10). Conclusions TP53 mutations and abnormal p53 expression in EC patients predict a poorer prognosis, characterized by increased RcR and MR, as well as lower DFS and OS. Graphical abstract
- 17 October 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (4) , 1324-1339
Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis
Background Endometrial cancer (EC) is the sixth most common female cancer and may rank fourth in cancer mortality by 2040. TP53 mutations and aberrant p53 expression are associated to aggressive tumor subtypes and poor prognosis, reducing overall survival (OS), disease-free survival, recurrence rates (RcR) and Mortality Risk (MR). The prognostic impact of TP53 mutations in EC remains unclear. Methods A systematic search was conducted in PubMed, Embase, and the Cochrane Library. Hazard ratios (HR) and Risk Ratios (RR) with 95% confidence intervals (CI) were combined using random-effects models. Analyses were conducted in RStudio (v4.4.1), and heterogeneity was evaluated using the I2 statistic, with p < 0.05 considered significant. Results Twenty-four studies comprising 5462 EC patients were included. TP53 mutations and aberrant p53 expression were associated with poorer outcomes. For OS, TP53 mutations had an HR of 2.27 (95% CI 1.47–3.49) and aberrant p53 had an HR of 5.01 (95% CI 2.44–10.30). For DFS, TP53 mutations had an HR of 4.20 (95% CI 1.79–9.86), while aberrant p53 had an HR of 2.17 (95% CI 1.27–3.72). TP53 mutations also increased RcR (RR: 2.88; 95% CI 2.18–3.80) and MR (RR: 2.33; 95% CI 1.11–4.88). Aberrant p53 showed a non-significant trend for recurrence (RR: 3.54; 95% CI 0.95–13.10). Conclusions TP53 mutations and abnormal p53 expression in EC patients predict a poorer prognosis, characterized by increased RcR and MR, as well as lower DFS and OS. Graphical abstract
- 19 May 2025
- Published by Taylor & Francis in Biomarkers
- Vol. 30 (4) , 315-326
CYP450 gene polymorphisms and the risk of taxane-induced neurotoxicity in breast cancer patients: a systematic review and meta-analysis
Breast cancer (BC) is the most common cancer in women. Taxanes are widely used, but their neurotoxicity affects patients' quality of life. Genetic polymorphisms in CYP450 enzymes influence taxane metabolism, leading to variability in toxicity risk. A literature search was conducted to identify studies on the association between CYP450 polymorphisms and Taxane-Induced Peripheral Neuropathy (TIPN) in BC patients. Odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) were estimated using a random-effects model in RStudio. Nine studies with 3034 patients were included. Overall CYP polymorphisms showed a significant association with TIPN (OR: 1.2877, 95% CI: 1.0262-1.6157). CYP1B1 polymorphism had an inconsistent link to TIPN by OR of 1.1524 (95% CI: 0.7441-1.7849). CYP2C8 polymorphism demonstrated the strongest association (OR: 1.5532, 95% CI: 1.2013-2.0082; HR: 1.5236, 95% CI: 1.1317-2.0512). CYP3A4 showed no significant association (OR: 1.0988, 95% CI: 0.5022-2.4404). CYP2C8 polymorphisms were significantly linked to TIPN. While CYP1B1 showed inconsistent results, CYP3A4 had no significant association. These findings imply that CYP2C8 genetic variations may affect taxane metabolism and neurotoxicity risk, indicating that pharmacogenomic profiling could help personalize chemotherapy and reduce adverse effects.
- 19 May 2025
- Published by Taylor & Francis in Biomarkers
- Vol. 30 (4) , 315-326
CYP450 gene polymorphisms and the risk of taxane-induced neurotoxicity in breast cancer patients: a systematic review and meta-analysis
Breast cancer (BC) is the most common cancer in women. Taxanes are widely used, but their neurotoxicity affects patients' quality of life. Genetic polymorphisms in CYP450 enzymes influence taxane metabolism, leading to variability in toxicity risk. A literature search was conducted to identify studies on the association between CYP450 polymorphisms and Taxane-Induced Peripheral Neuropathy (TIPN) in BC patients. Odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) were estimated using a random-effects model in RStudio. Nine studies with 3034 patients were included. Overall CYP polymorphisms showed a significant association with TIPN (OR: 1.2877, 95% CI: 1.0262-1.6157). CYP1B1 polymorphism had an inconsistent link to TIPN by OR of 1.1524 (95% CI: 0.7441-1.7849). CYP2C8 polymorphism demonstrated the strongest association (OR: 1.5532, 95% CI: 1.2013-2.0082; HR: 1.5236, 95% CI: 1.1317-2.0512). CYP3A4 showed no significant association (OR: 1.0988, 95% CI: 0.5022-2.4404). CYP2C8 polymorphisms were significantly linked to TIPN. While CYP1B1 showed inconsistent results, CYP3A4 had no significant association. These findings imply that CYP2C8 genetic variations may affect taxane metabolism and neurotoxicity risk, indicating that pharmacogenomic profiling could help personalize chemotherapy and reduce adverse effects.